This program is intended for community-based medical hematologists/oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with CLL.
The goal of this program is to improve the knowledge, confidence, and competence of multidisciplinary team learners in the care of patients with CLL using evidence-based and guideline-directed best practices.
Upon completion of this activity, participants should be able to:
Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, taking into consideration available clinical data, the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference
Appraise the differences in selectivity, binding, efficacy, and adverse event profiles of agents with a similar molecular target used to treat CLL/SLL
Develop multidisciplinary management plans for patients with CLL/SLL to optimize quality of life and address racial-related and age-related disparities in care
Manage treatment-related symptoms in patients with CLL/SLL using guidelines and expert recommendations based on real-world experience to optimally adjust, discontinue, or change the patient’s current therapeutic plan
Evaluate the evolving role of measurable/minimal residual disease, allogeneic hematopoietic cell transplant, CAR T-cell therapy, and other novel therapeutics for CLL/SLL
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Jennifer R. Brown, MD, PhD
Worthington & Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Director and Institute Physician,
Department of Medical Oncology
Dana-Farber Cancer Institute
Jennifer R. Brown, MD, PhD: consultant/advisor/speaker: AbbVie, Acerta, AstraZeneca, BeiGene, Bristol-Myers Squibb, Catapult, Celgene, Genentech/Roche, Hutchmed, iOnctura, Janssen, Juno, Lilly, MEI, Pharmacyclics; researcher: BeiGene, Gilead Sciences, Lilly, Loxo, MEI, SecuraBio, Sun, TG Therapeutics.
Jeff Sharman, MD
Medical Director of Hematology Research
Willamette Valley Cancer Institute
Jeff Sharman, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Lilly, Merck.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 01, 2023, through May 31, 2024:
1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.00 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-144-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to NABP CPE Monitor Service within 60 days.